J.P. Morgan 25th Annual
Healthcare Conference

Joseph S. Camardo, M.D.
Senior Vice President Global Medical
Affairs and No...
Forward-Looking Statement

    The statements in this presentation that are not historical facts are forward-
    looking ...
7 New Drugs - 11 Important Indications
    (October 5, 2006 Analyst Meeting)
    Today’s
     Talk
                  Prist...
Wyeth Development Pipeline: Robust and
                Deep
                Phase 0         Phase 1           Phase 2     ...
13-Valent Pneumococcal
Polysaccharide Conjugate
Vaccine (13v PnC)

Infants and Adults
Increasing Impact of Prevnar® in U.S.


                                   …in Children                                   ...
The Infant Vaccine Phase 3 Program
    Prevnar 13

         Objectives:
     n


           Demonstrate the Immunological ...
13v PnC Infant Product Profile


        The Most Complete Vaccine Available for the
        Global Prevention of Pneumoco...
The Adult Vaccine Phase 3 Program
    Prevnar 13
        Five Key Objectives:
    n

          Demonstrate robust Immunolo...
13v PnC Adult Product Profile


          The Vaccine of Choice for Adults 50 Years
          of Age and Older for the Pre...
Pristiq™ (DVS-233)
(Desvenlafaxine Succinate)
Pristiq™: A Single Product With Two
     Indications

                              Pristiq



                           ...
Pristiq™/Effexor XR®
   Comparable MDD Efficacy
                                                  Pooled Post-Hoc Analysis...
Pristiq™: Effective in Reducing
   Number of Moderate and Severe VMS
                                              Study 3...
Pristiq™: Safety and Tolerability Profile

                         Consistent With the SNRI Class
                       ...
Pristiq™ Low-Dose Program


      MDD
          3 Ongoing Low-Dose Studies
      n

            50, 100 mg, Placebo (2 Stu...
Pristiq™ Will Broaden the Reach of Our SNRI
     Franchise

                         Vasomotor      Major
                ...
Pristiq™ Product Profile for Major Depression
     or VMS

       Can Become the First and Only SNRI Proven
       to Effe...
Viviant™/Aprela™
   (Bazedoxifene) and
   (Bazedoxifene/Conjugated
   Estrogens)




Alliance with Ligand Pharmaceuticals
Viviant™ Product Profile
     (Bazedoxifene)




       To Be the First New SERM in Nearly 10
       Years Providing Physi...
Viviant™ Prevents Osteoporosis

                                                        Lumbar Spine BMD
                 ...
Viviant™: Analysis of Endometrial Effects

                                              Includes Clinically Significant E...
Viviant Clinical Profile


            Achieved Osteoporosis Prevention As Measured
        n

            by BMD
       ...
Aprela™: Optimal Targeted Response of
     Tissue Selective Estrogens Complex (TSEC)

                         Target     ...
Aprela™ Prevents Osteoporosis

                                                        Lumbar Spine BMD
                  ...
Aprela™ Effectively Treats Vasomotor
   Symptoms
                   Number of Moderate-to-Severe Symptoms
                ...
Aprela™ Bleeding Profile - No Breakthrough
   Bleeding
                    % Subjects With Amenorrhea Over 1 Year
        ...
Aprela™ Provided Excellent Endometrial and
     Breast Safety/Tolerability - Phase 3

               After 2 Years of Trea...
Aprela - The First TSEC
     A New Class for Menopausal Treatment

               Product Profile
           n

         ...
Aprela™ and Viviant™
     Comprehensive Menopausal Therapy




              TSEC                      SERM

            A...
Torisel™
(Temsirolimus)
Torisel™ Is the First New Drug Shown to
   Significantly Improve Survival in RCC

                                        ...
Overall Survival Extended by More Than 3
     Months With Torisel™

                             1.00
                    ...
Patients on Torisel™ Live Longer and
   Maintain Quality of Life
                  10                                     ...
Torisel™ Is Unique Among the New RCC Drugs


                         Torisel                    Nexavar                  ...
Torisel™ Is a Unique and Effective
     New Treatment for Renal Cell Cancer
      Only Agent to Show an RCC Survival Benef...
Bifeprunox




Alliance with Solvay in the
United States, Canada and Mexico
Bifeprunox: Study 10214 Efficacy

                                1.0
                                0.9
                ...
Bifeprunox: Study 10214 Safety

                                                            Mean Weight Change
          W...
Bifeprunox: Study 10214 Safety

                          % Patients with Metabolic Syndrome
               50%

         ...
Bifeprunox Safely Maintains Stability
   in Schizophrenia

             Relief for Patients Where Metabolic Changes
      ...
Methylnaltrexone




Alliance with Progenics
Methylnaltrexone Is a Selective Opioid
     Antagonist
                                                         CH3
     O...
Methylnaltrexone Is Active in Patients With
     Opioid Induced Constipation (OIC)
                                       ...
Methylnaltrexone Induces a
     Rapid and Predictable Response in OIC
                                      75%
          ...
Methylnaltrexone IV Accelerates Recovery in
     Post Operative Ileus (POI) - Phase 2 Data
            65 Patients With Se...
Methylnaltrexone: Future Standard for Rapid
     and Predictable Relief of Opioid Side Effects

          Novel Approach t...
Methylnaltrexone Product Profile


                        First Multi-Formulation Treatment
                        for P...
Late Stage Pipeline: The Next Wave of Launches
     NDA’s Filed or Expected to File in 2007

                          Lyb...
J.P. Morgan 25th Annual
Healthcare Conference

Joseph S. Camardo, M.D.
Senior Vice President Global Medical
Affairs and No...
Upcoming SlideShare
Loading in …5
×

wyeth JPMorgan 25th Annual Healthcare Conference

1,106 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,106
On SlideShare
0
From Embeds
0
Number of Embeds
13
Actions
Shares
0
Downloads
25
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

wyeth JPMorgan 25th Annual Healthcare Conference

  1. 1. J.P. Morgan 25th Annual Healthcare Conference Joseph S. Camardo, M.D. Senior Vice President Global Medical Affairs and North American Medical Director, Wyeth Pharmaceuticals January 9, 2007
  2. 2. Forward-Looking Statement The statements in this presentation that are not historical facts are forward- looking statements based on current expectations of future events that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, manufacturing, commercialization, economic conditions including interest and currency exchange rate fluctuations, the impact of competitive or generic products, product liability and other types of lawsuits, the impact of legislative and regulatory compliance and obtaining approvals, and patent, and other risks and uncertainties, including those detailed from time to time in Wyeth’s periodic reports, including quarterly reports on Form 10-Q and the annual report on Form 10- K, filed with the Securities and Exchange Commission. Quarterly results, in particular, can vary due to issues which include, but are not limited to, changes in exchange rates, the timing of actions taken by the Company to ensure long-term improvements to our manufacturing processes, the timing of regulatory approval of new products and/or facilities and the timing of promotional programs. Actual results may vary materially from the forward-looking statements. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. 2
  3. 3. 7 New Drugs - 11 Important Indications (October 5, 2006 Analyst Meeting) Today’s Talk Pristiq™ Major Depressive Disorder Pristiq™ Major Depressive Disorder Vasomotor Symptoms Vasomotor Symptoms Viviant™ Prevention/Treatment Osteoporosis Viviant™ Prevention/Treatment Osteoporosis Aprela™ Menopausal Symptoms/Osteoporosis Aprela™ Menopausal Symptoms/Osteoporosis Lybrel™ Contraception Lybrel™ Contraception Torisel™ Renal Cell Cancer Torisel™ Renal Cell Cancer Mantle Cell Lymphoma Mantle Cell Lymphoma Bifeprunox Schizophrenia Bifeprunox Schizophrenia Methylnaltrexone SC – Opioid Induced Constipation Methylnaltrexone SC – Opioid Induced Constipation IV – Post Operative Ileus IV – Post Operative Ileus Tygacil®* CAP/HAP Tygacil®* CAP/HAP * Tygacil already approved, not a new drug 3
  4. 4. Wyeth Development Pipeline: Robust and Deep Phase 0 Phase 1 Phase 2 Phase 3 Registration PLA-695 HCV-796 Aprela™ Lybrel™ SCA-171 SAM -315 Lecozotan Torisel™ MCL Continuous SKS-927 SAM -531 Prinaberel Tygacil® Contraception NRI-193 TTI-237 Methylnaltrexone (HAP/CAP) Pristiq™ (MDD) PPM-201 PAI-749 (PO) Bifeprunox (Bipolar) Viviant™ (Osteo) PPM-202 PAZ-417 PPM-204 Pristiq™ Pristiq™(VMS) SRA-444 MST-997 Bosutinib Fibromyalgia Torisel (Renal) GAP-134 LXR-623 (SKI-606) Pristiq™ Bifeprunox BLI-489 SLV-313 Vabicaserin (Neuropathic Pain) (Schizophrenia) SAM -610 SLV-314 (SCA-136) Methylnaltrexone Protonix ® Ad. SKI-015 PSI-697 HKI-272 (SC) PRA-027 Granules GSI-953 27330 - 550 9 13vPnC Adult Methylnaltrexone FXR-450 BeneFIX Reform. AGG-523 Enbrel – Asthma (IV) ILS-920 Mylotarg-AML (EU) HIV Vaccine (4) Bapineuzumab Lybrel™ PMDD BHS-019 MnB(2) GAP-486 Protonix ® Oral Ped HIV-001 ACC-001 MYO-029 Rapamune ® Liver CME-548 Inotuzumab TRU-015 (RA) 13vPnC Infant AAB-002 (CMC-544) BMP-2 Inject. ReFacto ® AF ILV-094 IMA-638 TRU-015 (Onc) Small Molecules Vaccines Proteins Phase 0 Phase 1 Phase 2 Phase 3 Registration 16 22 15 15 7 12/21/06
  5. 5. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (13v PnC) Infants and Adults
  6. 6. Increasing Impact of Prevnar® in U.S. …in Children … and Adults (>50 Years of Age) Average Incidence of Vaccine Serotype 90 35 Prelicensure Prelicensure 80 30 (1998-1999) (1998-1999) IPD per 100,000 Population Estimated Cases/100,000 70 Postlicensure Postlicensure 25 60 (2003) (2002-2003) 55% 20 50 40 Reduction 15 94% 30 10 Reduction 20 5 10 0 0 Average for 2003 Average for 2003 1998 and 1999 1998 and 1999 MMWR. 2005;Vol: 54(No. 36):893-897. 6
  7. 7. The Infant Vaccine Phase 3 Program Prevnar 13 Objectives: n Demonstrate the Immunological Non-Inferiority of 13v PnC to 7-valent Prevnar® in Young Infants Demonstrate That 13v PnC Does Not Interfere With Immune Responses Elicited by Concomitantly Administered Childhood Vaccines Demonstrate Immunological Consistency Across Multiple Production Batches of the Vaccine Demonstrate the Vaccine’s Safety and Tolerability The Program Will Involve Approximately 4,000 Children n 7
  8. 8. 13v PnC Infant Product Profile The Most Complete Vaccine Available for the Global Prevention of Pneumococcal Disease and Otitis Media Phase 2 Proof of Concept Achieved n Licensing Criteria Agreed Upon n Status Worldwide Phase 3 Studies n Ongoing Submission – Early 2009 n 8
  9. 9. The Adult Vaccine Phase 3 Program Prevnar 13 Five Key Objectives: n Demonstrate robust Immunological responses for 13v PnC in adults >50 Years of Age Demonstrate That 13v PnC Can Enhance the Anti-Polysaccharide Responses in Adults Previously Immunized With the 23-valent Vaccine Demonstrate That Initial Immunization With 13v PnC Does Not Cause Immunological Hyporesponsiveness Demonstrate That 13v PnC Does Not Interfere With the Immune Response to Concomitantly Administered Influenza Virus Vaccine Demonstrate the Vaccine’s Safety and Tolerability The Program Will Involve Approximately 3,200 Adults n 9
  10. 10. 13v PnC Adult Product Profile The Vaccine of Choice for Adults 50 Years of Age and Older for the Prevention of Pneumococcal Disease Proof of Concept Achieved n Licensing Criteria Being Finalized n Status Worldwide Phase 3 Clinical n Studies to Begin in Early 2007 Submission 2009 n 10
  11. 11. Pristiq™ (DVS-233) (Desvenlafaxine Succinate)
  12. 12. Pristiq™: A Single Product With Two Indications Pristiq Vasomotor Symptoms Depression Positioning Positioning First Line Treatment of First FDA-Approved Major Depressive Disorder Non-Hormonal Treatment of Associated With Menopause Moderate-to-Severe VMS 12
  13. 13. Pristiq™/Effexor XR® Comparable MDD Efficacy Pooled Post-Hoc Analysis 0 -2 -4 Change from Baseline Ham-D 17 Total -6 Pristiq 200-400 mg -8 * * Placebo -10 * Effexor XR * 75-150 mg -12 * ** Effexor XR 150-225 mg * -14 * * * -16 1 2 3 4 5 6 7 8 Week * P < 0.05 vs placebo DVS 309-EU and 317-US: Pooled Analysis Ham-D17 Total Score (Mixed Effect Model, ITT) 13
  14. 14. Pristiq™: Effective in Reducing Number of Moderate and Severe VMS Study 315 Study 319 13 13 12 12 11 11 10 10 # of Flushes 9 # of Flushes 9 8 8 Placebo Placebo 7 7 6 6 Pristiq 150 mg 5 5 Pristiq 100 mg Pristiq 4 4 100 mg Pristiq 150 mg 3 3 2 2 0 1 2 3 4 56 7 8 9 10 11 12 0123 45 678 9 10 11 12 Weeks Weeks 100 mg dose: p-value versus placebo < 0.05 at all time points 150 mg dose: p-value versus placebo < 0.05 at all time points 14
  15. 15. Pristiq™: Safety and Tolerability Profile Consistent With the SNRI Class Asthenia Nervousness Hypertension Somnolence Anorexia Tremor Constipation Sweating Dry Mouth Abnormal Vision Nausea Mydriasis Vomiting Abnormal Ejaculation/Orgasm Impotence (Male) Dizziness Insomnia (Adverse Reactions ≥ 5%)* *Most common adverse drug reactions (>5%), pooled data VMS+MDD 15
  16. 16. Pristiq™ Low-Dose Program MDD 3 Ongoing Low-Dose Studies n 50, 100 mg, Placebo (2 Studies U.S., EU) 50, 100 mg, Placebo, Duloxetine 1 Low-Dose Study to Support Registration in Asia n Additional Low-Dose Drug-Drug Interaction Studies n Underway VMS Titration Study – 25, 50, 100 mg (Ongoing) n 16
  17. 17. Pristiq™ Will Broaden the Reach of Our SNRI Franchise Vasomotor Major Vasomotor Major Fibromyalgia Fibromyalgia Depressive Symptoms of Depressive Symptoms of Syndrome Syndrome Menopause Disorder Menopause Disorder Generalized Generalized Anxiety Anxiety Disorder Disorder Social Social Anxiety Anxiety Green = Effexor XR® Disorder Disorder Blue = Pristiq™ Panic Panic Disorder Red = Effexor/Pristiq Disorder 17
  18. 18. Pristiq™ Product Profile for Major Depression or VMS Can Become the First and Only SNRI Proven to Effectively Address the Distinctive Symptoms and Therapeutic Needs of Women With Depression Associated With Menopause or Vasomotor Symptoms MDD NDA Dec 2005 Status VMS NDA June 2006 18
  19. 19. Viviant™/Aprela™ (Bazedoxifene) and (Bazedoxifene/Conjugated Estrogens) Alliance with Ligand Pharmaceuticals
  20. 20. Viviant™ Product Profile (Bazedoxifene) To Be the First New SERM in Nearly 10 Years Providing Physicians a New Option for Patients at Risk of Osteoporosis and Fracture 20
  21. 21. Viviant™ Prevents Osteoporosis Lumbar Spine BMD Phase 3 Study 1.00 Viviant 40 mg Adjusted Percent Change Raloxifene 60 mg 0.00 Viviant 20 mg Placebo Viviant 10 mg -1.00 -2.00 Baseline Month 6 Month 12 Month 18 Month 24 p <0.001 vs. placebo for all BZA groups at each time point No statistically significant differences among BZA 10, 20, 40 mg at any time point 21
  22. 22. Viviant™: Analysis of Endometrial Effects Includes Clinically Significant Endometrial Thickness, Hyperplasia, Polyp, and Carcinoma % Patients With Endometrial Treatment 5 Emergent Adverse Events 4 3 2 * * 1 0 Viviant ™ 10 Placebo Viviant 20 Viviant 40 Raloxifene 60 * Statistically significant to RLX and PCB 22
  23. 23. Viviant Clinical Profile Achieved Osteoporosis Prevention As Measured n by BMD Good Endometrial Safety Profile n No Increase in Hyperplasia, Polyps, or Thickness Side Effect Profile: Increase From Placebo n Hot Flush Venous Thrombosis Leg Cramps Less Breast Tenderness Versus Placebo n 23
  24. 24. Aprela™: Optimal Targeted Response of Tissue Selective Estrogens Complex (TSEC) Target TSEC Increased Bone Mass Improved Hot Flush Vaginal Health Prevent Endometrial Hyperplasia Decreased Breast Tenderness The Most Comprehensive Medicine for Menopause 24
  25. 25. Aprela™ Prevents Osteoporosis Lumbar Spine BMD Phase 3 Study 2.0 * * Aprela 20/0.625 1.5 * * * Aprela 20/0.45 1.0 * * Adjusted Mean % Change 0.5 * 0.0 Raloxifene -0.5 -1.0 Placebo -1.5 BMD Change Relative to Placebo: -2.0 20/0.625: ↑ 3.72% at 2y 20/0.45: ↑ 3.61% at 2y -2.5 Baseline Month 6 Month 12 Month 18 Month 24 p vs PBO ≤ 0.001 (all BZA/CE groups at 6, 12, 18 and 24m) * p vs RAL < 0.05 25
  26. 26. Aprela™ Effectively Treats Vasomotor Symptoms Number of Moderate-to-Severe Symptoms Phase 3 Study 0 Placebo -2 Adjusted Mean Change From Baseline Raloxifene -4 -6 Aprela 20/0.625 -8 Aprela 20/0.45 -10 0 1 2 3 4 5 6 7 8 9 10 11 12 Week Statistically significant at all end points vs placebo and 8 – 12 weeks vs raloxifene Data on file: Ph 3 BZA/CE analysis 3115A1-303 study 26
  27. 27. Aprela™ Bleeding Profile - No Breakthrough Bleeding % Subjects With Amenorrhea Over 1 Year Comparison to Prempro™ by Historical Data 100% 80% 60% Placebo 40% Aprela™ 20/0.625 Aprela 20/0.45 20% CE/MPA 0.45/1.5 CE/MPA 0.625/2.5 0% 1 2 3 4 5 6 7 8 9 10 11 12 13 Months Data on file: Ph 3 BZA/CE analysis 3115A1-303 study 27
  28. 28. Aprela™ Provided Excellent Endometrial and Breast Safety/Tolerability - Phase 3 After 2 Years of Treatment With Aprela n Endometrium - No Difference From Placebo - Endometrial Hyperplasia - Endometrial Thickness - Endometrial Polyps Breast - No Difference in Breast Tenderness vs. Placebo - No Difference in Breast Tenderness vs. Raloxifene - No Increased Breast Cancers 28
  29. 29. Aprela - The First TSEC A New Class for Menopausal Treatment Product Profile n Relieves Vasomotor Symptoms Prevents Osteoporosis Improves Vulvovaginal Atrophy (VVA) Excellent Amenorrhea Less Breast Tenderness Provides Endometrial Protection Without Progestin NDA Filing: Late 2007 n Most Significant Medical Advance in Menopausal Therapy 29
  30. 30. Aprela™ and Viviant™ Comprehensive Menopausal Therapy TSEC SERM Aprela Viviant (Bazedoxifene/CE ) (Bazedoxifene) Vasomotor Symptoms Osteoporosis Prevention Vulvovaginal Atrophy Osteoporosis Treatment Osteoporosis Prevention 30
  31. 31. Torisel™ (Temsirolimus)
  32. 32. Torisel™ Is the First New Drug Shown to Significantly Improve Survival in RCC Interferon Torisel Interferon + Torisel Patients 209 207 210 # Deaths 143 149 152 Median Overall 10.9 mo 7.3 mo 8.4 mo Survival % Improvement in 49% 15% Survival Log Rank p-Value 0.0078 0.6965 Stratified Based on Data for Wyeth NDA 32
  33. 33. Overall Survival Extended by More Than 3 Months With Torisel™ 1.00 From ARCC Study Survival Distribution 0.75 Torisel Function 0.50 IFN 0.25 7.3 mo 10.9 mo 0.00 0 5 10 15 20 25 30 Time to Death (Months) 33
  34. 34. Patients on Torisel™ Live Longer and Maintain Quality of Life 10 * Torisel 8 * Interferon Torisel Months 6 Interferon 4 2 0 TWiST Q-TWiST Torisel Extends Time Without Symptoms of Progression or Toxicity * Torisel significantly better, p=.0005 34
  35. 35. Torisel™ Is Unique Among the New RCC Drugs Torisel Nexavar Sutent (Current Indication) Study 1st Line Poor/ Intermediate 2nd Line Good/ 1st Line Good/ Population Prognosis Intermediate Prognosis Intermediate Prognosis N = 769 Patients N=750 N = 626 Patients Comparator Interferon Placebo Interferon Survival No Significant No Significant 49% Improvement Improvement Improvement 10.9 vs. 7.3 Months Progression- 77% Improvement 99% Improvement 120% Improvement free Survival 5.5 vs. 3.1 Months 5.9 vs. 2.8 Months 11 vs. 5 Months 35
  36. 36. Torisel™ Is a Unique and Effective New Treatment for Renal Cell Cancer Only Agent to Show an RCC Survival Benefit Torisel Alone Improves Overall Survival (49%) in n Patients With Advanced Renal Cell Cancer Median Increase in Survival Is 3.6 Months The Result Is Clinically Significant and Highly Statistically Significant Effective in Patients With Poor and Intermediate Prognosis Torisel Also Preserves Patients’ Quality of Life n Positions Torisel to Be RCC Drug of Choice 36
  37. 37. Bifeprunox Alliance with Solvay in the United States, Canada and Mexico
  38. 38. Bifeprunox: Study 10214 Efficacy 1.0 0.9 0.8 Kaplan-Meier Estimates Bifeprunox 30 mg 0.7 0.6 0.5 Bifeprunox 20 mg 0.4 0.3 Placebo 0.2 p-Value = 0.008 0.1 0.0 0 30 60 90 120 150 180 Time in Days Bifeprunox Patients Remained Relapse-Free Longer Than Placebo Patients Over 6 Months 38
  39. 39. Bifeprunox: Study 10214 Safety Mean Weight Change Weight Change From Baseline (Lbs) 0 -1 -2 -3 * -4 -5 Placebo Bifeprunox 20 mg Bifeprunox 30 mg Bifeprunox Patients Lost Weight on Average After 6 Months * p < 0.05 bifeprunox versus placebo 39
  40. 40. Bifeprunox: Study 10214 Safety % Patients with Metabolic Syndrome 50% 40% 30% End of Baseline Study End of Baseline 20% Study End of Baseline Study 10% 0% Placebo Bifeprunox 20 mg Bifeprunox 30 mg Bifeprunox Did Not Cause Metabolic Syndrome Definition of assessable: 4 or more MS criteria have been measured MS present: 3 or more MS criteria are fulfilled 40
  41. 41. Bifeprunox Safely Maintains Stability in Schizophrenia Relief for Patients Where Metabolic Changes n Have Challenged Their Long-Term Therapy Effective at Maintaining Stability in Chronic Patients n Improved Side Effect Profile n No Weight Gain Favorable Lipid Profile Minimal Risk for Glucose Dysregulation Lack of Hyperprolactinemia Status NDA October 2006 * Sales for Wyeth / Solvay Alliance territories only; the United States, Canada and Mexico Alliance with Solvay Pharmaceuticals 41
  42. 42. Methylnaltrexone Alliance with Progenics
  43. 43. Methylnaltrexone Is a Selective Opioid Antagonist CH3 Opioids Activate Receptors Morphine Acts Centrally and n in the Brain and Provide Pain Relief… Peripherally N Morphine Methylnaltrexone Is a Mu n Opioid Receptor Antagonist Does Not Cross the n HO O OH Blood-Brain Barrier Antagonizes Peripheral, but n CH3 Not Central Opioid Receptors Methylnaltrexone N+ Reverses Opioid Induced n Constipation Without HO Reversing Analgesia or Inducing Withdrawal … But Receptor Activation in the GI Tract Results in HO O O Constipation. 43
  44. 44. Methylnaltrexone Is Active in Patients With Opioid Induced Constipation (OIC) > 50% of Patients Have Bowel Movement Within 4 Hours (Study 301) 70 % Patients Having Bowel Movement 60 50 40 30 20 10 0 Placebo 0.15 mg/kg 0.30 mg/kg Recommended Dose 44
  45. 45. Methylnaltrexone Induces a Rapid and Predictable Response in OIC 75% 30 m inutes 0.30 mg/kg % Patients Having Bowel Movement 0.15 mg/kg 50% 25% Placebo 0% 0 4 1 2 3 5 Hours Study 301 Recommended Dose 45
  46. 46. Methylnaltrexone IV Accelerates Recovery in Post Operative Ileus (POI) - Phase 2 Data 65 Patients With Segmental Colectomies n Randomized to Methylnaltrexone IV or Placebo Evaluated for Clinical Signs Indicating Recovery of Bowel Function and Readiness for Discharge Acceleration Time to Post-Operative Recovery Endpoint (On Average) Tolerance of First Solid Meal (P=0.12) 25 Hours First Bowel Movement (P=0.01) 23 Hours Discharge Eligibility 30 Hours (P=0.03) Actual Discharge 25 Hours (P=0.09) Discharge a Day Early 46
  47. 47. Methylnaltrexone: Future Standard for Rapid and Predictable Relief of Opioid Side Effects Novel Approach to Control of Opioid Side Effects n Relieves Constipation and Allows Maintenance of Pain Control Phase 3 (SC) Data Show Positive Results in Patients n With Advanced Illness Whose Palliative Care Includes Opioids Phase 2 (IV) Studies - Positive Results for Post n Surgical Recovery of Bowel Function Drug Was Generally Well Tolerated n 47
  48. 48. Methylnaltrexone Product Profile First Multi-Formulation Treatment for Peripheral Opioid Side Effects SC – NDA Early 2007 (1st for OIC) Status IV – Phase 3: File Late 2007 or Early 2008 (1st /Only IV) Oral – Phase 2: File Late 2008 or Early 2009 (OIC) Development Collaboration With Progenics 48
  49. 49. Late Stage Pipeline: The Next Wave of Launches NDA’s Filed or Expected to File in 2007 Lybrel Contraception Lybrel Contraception 2005 Pristiq Major Depressive Disorder Pristiq Major Depressive Disorder Pristiq Vasomotor Symptoms Pristiq Vasomotor Symptoms Viviant Osteoporosis Prevention Viviant Osteoporosis Prevention 2006 Torisel Renal Cell Cancer Torisel Renal Cell Cancer Bifeprunox Schizophrenia Bifeprunox Schizophrenia Viviant Osteoporosis Treatment Viviant Osteoporosis Treatment Aprela Menopausal Symptoms/Osteoporosis Aprela Menopausal Symptoms/Osteoporosis 2007 Torisel Mantle Cell Lymphoma Torisel Mantle Cell Lymphoma Methylnaltrexone SC – Opioid Induced Constipation Methylnaltrexone SC – Opioid Induced Constipation IV – Post Operative Ileus IV – Post Operative Ileus Tygacil* CAP/HAP Tygacil* CAP/HAP * Tygacil already approved, not a new drug 49
  50. 50. J.P. Morgan 25th Annual Healthcare Conference Joseph S. Camardo, M.D. Senior Vice President Global Medical Affairs and North American Medical Director, Wyeth Pharmaceuticals January 9, 2007

×